Comparative Safety of Ustekinumab and Vedolizumab in Older Patients with Inflammatory Bowel Disease: A Bicentric Cohort Study
Abstract
Introduction: Data about the safety of vedolizumab and ustekinumab are lacking in older patients with inflammatory bowel disease. The objective was to compare the safety of vedolizumab and ustekinumab therapies in older patients (>60 years) with inflammatory bowel disease. Methods: This retrospective study included patients with Crohn’s disease or ulcerative colitis initiating vedolizumab, ustekinumab or anti-TNF therapy at >60 years of age. We examined the occurrence of adverse events within one year after therapy. Results: This study included 182 patients: 53 were treated with vedolizumab (22 patients with Crohn’s disease and 31 with ulcerative colitis), 31 with ustekinumab (30 Crohn’s disease and one ulcerative colitis) and 98 with anti-TNF (63 Crohn’s disease and 35 ulcerative colitis). At one year, there was no difference in terms of safety in patients with Crohn’s disease between vedolizumab and ustekinumab considering the number of adverse events per year of follow-up (p = 0.258). For ulcerative colitis and Crohn’s disease, the occurrence of adverse events per year of follow-up was similar between vedolizumab and anti-TNF (p = 0.274 and p = 0.876, respectively). Conclusions: Safety was similar between vedolizumab and ustekinumab in older patients with inflammatory bowel disease.
Related
- Comparative efficacy and safety of subcutaneous vedolizumab versus other targeted inflammatory bowel therapies in patients with moderate to severe ulcerative colitis: a network meta-analysis update.
- Ustekinumab for Extraintestinal Manifestations in Patients With Inflammatory Bowel Disease: Lessons From the TENOR Real-World Study.
- Inflammatory Bowel Disease Patients’ Acceptance for Switching from Intravenous Infliximab or Vedolizumab to Subcutaneous Formulation: The Nancy Experience
- Associations between redox-related biomarkers and treatment response in patients with inflammatory bowel disease initiating infliximab or vedolizumab
- A real-world study of healthcare resource utilization and costs in patients with Crohn's disease and ulcerative colitis initiating ustekinumab treatment via Johnson & Johnson's BIOADVANCE program.
BibTeX
@article{burgevin2026comparative,
title = {{Comparative Safety of Ustekinumab and Vedolizumab in Older Patients with Inflammatory Bowel Disease: A Bicentric Cohort Study}},
author = {Alice Burgevin and Bénédicte Caron and Alexa Sasson and Amandine Luc and Patrick Netter and Cédric Baumann and Ashwin Ananthakrishnan and Laurent Peyrin‐biroulet},
journal = {Journal of Clinical Medicine},
year = {2026},
month = sep,
doi = {10.3390/jcm11236967},
url = {https://hal.univ-lorraine.fr/hal-04168322v1},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Comparative Safety of Ustekinumab and Vedolizumab in Older Patients with Inflammatory Bowel Disease: A Bicentric Cohort Study
AU - Alice Burgevin
AU - Bénédicte Caron
AU - Alexa Sasson
AU - Amandine Luc
AU - Patrick Netter
AU - Cédric Baumann
AU - Ashwin Ananthakrishnan
AU - Laurent Peyrin‐biroulet
PY - 2026
DA - 2026/09/04
JO - Journal of Clinical Medicine
DO - 10.3390/jcm11236967
UR - https://hal.univ-lorraine.fr/hal-04168322v1
AB - Introduction: Data about the safety of vedolizumab and ustekinumab are lacking in older patients with inflammatory bowel disease. The objective was to compare the safety of vedolizumab and ustekinumab therapies in older patients (>60 years) with inflammatory bowel disease. Methods: This retrospective study included patients with Crohn’s disease or ulcerative colitis initiating vedolizumab, ustekinumab or anti-TNF therapy at >60 years of age. We examined the occurrence of adverse events within one year after therapy. Results: This study included 182 patients: 53 were treated with vedolizumab (22 patients with Crohn’s disease and 31 with ulcerative colitis), 31 with ustekinumab (30 Crohn’s disease and one ulcerative colitis) and 98 with anti-TNF (63 Crohn’s disease and 35 ulcerative colitis). At one year, there was no difference in terms of safety in patients with Crohn’s disease between vedolizumab and ustekinumab considering the number of adverse events per year of follow-up (p = 0.258). For ulcerative colitis and Crohn’s disease, the occurrence of adverse events per year of follow-up was similar between vedolizumab and anti-TNF (p = 0.274 and p = 0.876, respectively). Conclusions: Safety was similar between vedolizumab and ustekinumab in older patients with inflammatory bowel disease.
SN - 2077-0383
ER -